Lupin Launches Generic Sugammadex Injection in US Following FDA Approval
Pharma company Lupin has launched its generic Sugammadex Injection in the United States after receiving approval from the US Food and Drug Administration for its abbreviated new drug application. The injection, available in 200 mg and 500 mg single-dose vials, is bioequivalent to Merck's Bridion Injection. It is used to reverse neuromuscular blockade caused by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged two years and older undergoing surgery.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (52/100). Lens Score 38/100.
Outlets measured: economictimes, news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 31 Jul, 07:24 am. Other outlets followed.